Merck

Pharmaceutical giant Merck is partnering with startup Seeqc to monitor quantum developments while keeping an open mind.

Merck said Tuesday it has entered voluntary licensing agreements with five Indian generic drug makers to expand access to molnupiravir, an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. "The scale of human suffering in India at this moment is devastating, and it is clear that more must be done to help alleviate it," Merck Chief Executive Kenneth C. Frazier said in a statement. The agreements are with Limited, Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited, five companies with experience as major suppliers to global procurers. Merck will also donate more than $5 million worth of oxygen-production equipment, masks, hand sanitizers and financial aid to support relief efforts in India. Shares were flat premarket and are down 5% in the year to date, while the S&P 500 has gained 11.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Inhaled Nitric Oxide Market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period. Nitric oxide is a molecule of gas that causes a sense of relaxation in smooth muscle cells in the vasculature. It is because Nitric Oxide reacts with oxyhemoglobin. The gas is quickly collected by oxyhemoglobin in red blood cells and the vasodilating effects caused by inhaled nitric oxide are restricted to oxygenated areas of the lungs. Thus, this distinct ability of Nitric oxide to cause pulmonary vasodilatation in the oxygenated regions of the lung helps in enhancing oxygenation of the blood and reduces intrapulmonary right to left shunting. Hence, the inhaled nitric oxide is utilized to cure various cardiopulmonary conditions, like pulmonary hypertension in adults and children. Although, the usage of inhaled nitric oxide is restricted due to logistical and financial reasons.The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the global inhaled nitric oxide market during the forecast period.The declaration of WHO about the Covid-19 outbreak as a public health emergency has affected every country around the globe. During the pandemic, nitric oxide got under several experiments to test whether it can help in treating Covid-19 affected people, due to its antiviral properties and enhanced oxygenation. Inhaled Nitric Oxide is useful in safeguarding the frontline healthcare workers from this pandemic.Application OutlookBased on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Neonatal respiratory treatment segment procured the substantial revenue share and is estimated to exhibit high growth rate during the forecast period. This is due a surge in the occurrences of diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). The chronic obstructive pulmonary disease segment is expected to display promising growth rate during the forecast period.Regional OutlookBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the global inhaled nitric oxide market in 2019. The high growth of the regional market is due to the large consumer base & rising funding in R&D by the leading players. Major determinants such as surge in rates of chronic diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) are expected to support the market growth.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.Unique Offerings from the Publisher

In a return to its roots, Merck will be moving its global headquarters back to the city, and that's welcome news to Mayor Raymond Giacobbe. Giacobbe announced the news as part of his virtual 2021 State of the City address last week. Merck plans to relocate its headquarters from Kenilworth to Rahway last year.

Drugmaker Merck said Thursday it was ending plans to continue to study the experimental coronavirus drug molnupiravir in hospitalized coronavirus patients, but will continue to a Phase 3 in individuals who were recently infected.

EMD Electronics, a business of Merck KGaA (Darmstadt, Germany) announced an investment of €20 million to expand research and development and manufacturing capabilities at its site in Shizuoka, Japan. As part of this plan, new infrastructure will be built to advance and accelerate innovations in the electronic materials space. The investment is scheduled to be completed by January 2022.